



Hypertension Guidelines and Updates

Jay D Geoghagan, MD FACC



Disclosures: None



Hypertension Guidelines

- Where are we?
- How did we get here?
- What do we do now?



HTN: Too Many Recommendations?

- JNC
- ACC/AHA
- ASH/ISH
- ESH/ESC
- AAFP
- ADA



Who Are the Major Players?

- Joint National Committee ... (JNC)
 - JNC 1 - 1977 to JNC 7 – 2003
 - JNC 1-3 focused on DBP only
 - Officially there is no “JNC 8”
 - ACC/AHA/ASH
 - ESC/ESH
 - Others with specific interests



Diagnostic Threshold

- Varies across guidelines
 - Most common 140/90 mmHg
 - Some recommend 130/80 mmHg
- Methodologies differ
- Cardiovascular risk scores and comorbidities incorporated by some
- Mostly important for epidemiology and with “certain” patients



Treatment Targets

Organization	Population	Target BP	Risk Assessment
JNC 7 (2003)	Adults → DM/CKD →	< 140/90 mmHg < 130/80 mmHg	No
"JNC 8" (2014)	< 60 yo → > 60 yo →	< 140/90 mmHg < 150/90 mmHg	No
ACC/AHA (2017)	All adults	< 130/80 mmHg	Yes (Formal Risk score)
ESC/ESH (2018)	All adults initial → If tolerated → > 80 yo →	< 140/90 mmHg < 130/80 mmHg SBP < 160 mmHg ***	Yes (Risk estimation)



Treatment Caveats

- Withdrawing BP meds based on age alone is not recommended.
- Treatment of elderly patients is based on biologic age and not chronologic age
- When first diagnosed, low risk patients with mild HTN can be treated with 6 months of diet/lifestyle modifications
- Non-pharmacologic treatments should always be emphasized



“General” Points of Agreement

- Emphasis on confirming the diagnosis
- Emphasis on lifestyle modifications as active therapy
- Goal BP < 140/90 mmHg for all adults (if tolerated in elderly also)
- Goal BP < 130/80 mmHg for some patients
- Treat high risk patients more aggressively
- Emphasis on confirming the diagnosis



“General” Points of Agreement

- Single pill combination therapy may improve efficacy and compliance
- Beta-blockers are not indicated as first line therapy for uncomplicated HTN
- Causes of resistant hypertension are often obvious
- Treatment of the elderly is beneficial but must be based on patient “fitness” and tolerability



Concerns about Recent Guidelines

- Some groups, including the AAFP, did not endorse the 2017 ACC/AHA guidelines
- Possible conflict of interest in the 2017 guidelines
 - Specifically related to the SPRINT trial
- Concern regarding risk/benefit ratio of lower BP targets
- Method of BP measurement in SPRINT
- Validation of the risk assessment tool



Harmony?!?

Can't we all just get along?

“Harmony” of the Guidelines

- Confirm the diagnosis
- Lifestyle counseling for all and first line treatment for low risk, mild HTN.
- Initial BP target of < 140/90 mmHg for all adults with exception for frail, elderly patients
- Further goal of $\leq 130/80$ mmHg based on overall risk and tolerance of therapy
- Assessment of CV risk by some mechanism is important



“Harmony” of the Guidelines

- Early use of combination therapy, preferably in a single pill
- ACEI/ARBs, CCBs, and diuretics are first line drugs in most patients
- Resistant HTN is often caused by obesity, high sodium diet, excessive alcohol, untreated sleep apnea, and NSAIDS



Did You Know?

- The “controversial” 2017 ACC/AHA lower HTN definition did expand the number of people labeled as hypertensive.
- Number recommended treatment was only slightly increased because lifestyle modification was heavily endorsed.



Practical Recommendations

- State target BP in your A/P so that others will know your goal.
- Outline your plan to include non-Rx therapy as well as a timeline.
- If deviating from guidelines, outline the reasons.



Thank You

